Skeletal Muscle Relaxants Flashcards
MOA of succinylcholine
Agonist at nicotinic acetylcholine receptors causing an initial twitch, then persistent depolarization
Interactions of succinylcholine with other autonomic receptors
Stimulates ANS ganglia and muscarinic receptors.
Has slight ability to release histamine.
How is succinylcholine inactivated?
Phase I depolarization cannot be inactivated.
Phase II depolarization is inactivated by acetylcholinesterase inhibitors, such as neostigmine or pyridostigmine.
*NB: the paralysis produced during phase I is actually INCREASED by acetylcholinesterase inhibitors.
Adverse effects of succinylcholine
- Muscle pain. To prevent skeletal muscle fasciculation and the resulting postoperative pain, a small non paralyzing dose of a non depolarizing drug (such as cisatracurium) is often given immediately before succinylcholine.
- Hyperkalemia, especially in patients with burn or spinal cord injury, peripheral nerve dysfunction, or muscular dystrophy.
- Hypercalcemia
- Increased intragastric pressure (caused by fasciculations). Regurgitation and aspiration of gastric contents are possible complications of this.
* NB this complication is more likely in patients with delayed gastric emptying, such as those with esophageal dysfunction or diabetes. - Increased intraocular pressure
MOA of non depolarizing skeletal muscle relaxants (SMRs)
Competitive antagonists at skeletal muscle nicotinic acetylcholine receptors.
Nondepolarizing SMR most often associated with hypotension caused by histamine release
Tubocurarine
*NB: tubocurarine also weakly blocks ANS ganglia
Distinctive characteristic of pancuronium
Can block muscarinic receptors, especially those in the HEART. Has sometimes been caused tachycardia and hypertension and may cause dysrhythmias in predisposed individuals.
How do you reverse the effects of non depolarizing SMRs?
- Acetylcholinesterase inhibitors.
- Muscarinic blocking agents, such as glycopyrrolate or atropine. (Glycopyrrolate is preferred because it lacks CNS effects)
Rationale: Acetylcholinesterase inhibitors reverse the effects of non depolarizing SMRs by overcoming the competitive inhibition. However, administration of acetylcholinesterase inhibitors will increase the concentration of ACh in the synaptic clefts everywhere, including at muscarinic receptors, where they can cause bradycardia. Therefore you must give muscarinic blocking agents, in order that the acetylcholinesterase inhibitors have effects at nicotinic acetylcholine receptors only.
Histamine release is an adverse effect of which 2 non depolarizing SMRs?
tubocurarine
mivacurium
Which non depolarizing SMR causes laudanosine formation, which theoretically could lower the seizure threshold in a susceptible patient?
atracurium
What other drugs potentiate skeletal muscle relaxation of non depolarizing blockers?
Inhaled anesthetics, aminoglycosides, and possibly quinidine
Nondepolarizing blockers listed in K&T
tubocurarine, atracurium, cistracurium, mivacurium, rocuronium, vecuronium
MOA of baclofen
Facilitates SPINAL inhibition of motor neurons via GABA(b) receptor activation: pre- and postsynaptic
*NB: GABA(b) receptors are coupled to K+ channels, unlike GABA(a) receptors, which are coupled to Cl- channels, and are modulated by BDZs
What is baclofen used for?
CHRONIC spasmolytic therapy, in diseases such as cerebral palsy, MS, and stroke that are associated with hyperreflexia/painful spasms
MOA of cyclobenzaprine
Unknown. Believed to act in the brain stem, possibly by interfering with polysynaptic reflexes that maintain skeletal muscle tone.